TY - JOUR
T1 - Efficacy of anti-VEGF therapy for Irvine-Gass syndrome
T2 - a systematic review and meta-analysis
AU - Balsby, Daniel
AU - Arnold-Vangsted, Andreas
AU - Rosenørn, Emil Alexander
AU - Eriksen, Nathalie Skovgaard
AU - Ahmed, Hassan Javed
AU - Krarup, Therese Grønhøj
AU - Klefter, Oliver Niels
AU - Hajari, Javad Nouri
AU - Subhi, Yousif
AU - Schneider, Miklos
N1 - © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2026/1/20
Y1 - 2026/1/20
N2 - PURPOSE: To investigate the efficacy of intravitreal anti-VEGF agents in the treatment of Irvine-Gass syndrome (IGS).METHODS: Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.RESULTS: Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.CONCLUSION: Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.
AB - PURPOSE: To investigate the efficacy of intravitreal anti-VEGF agents in the treatment of Irvine-Gass syndrome (IGS).METHODS: Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.RESULTS: Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.CONCLUSION: Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.
U2 - 10.1007/s00417-025-07059-2
DO - 10.1007/s00417-025-07059-2
M3 - Review
C2 - 41557186
SN - 0721-832X
JO - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
JF - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ER -